Strategic Shift in Biotech Dealmaking
Pharmaceutical companies are increasingly focusing on late-stage biotech assets with clinical validation, making firms like Oncotelic Therapeutics strategic targets. Oncotelic Therapeutics has expanded its intellectual property for OT-101 in neurology and oncology and demonstrated strong performance in trials, including securing a patent for Parkinson's in Australia, solidifying its potential for commercialization. The company's R&D strategy targets the TGF-β signaling pathway, offering strategic flexibility and value across both oncology and neurological diseases.
Supernus Pharmaceuticals (SUPN) Projected to Post Quarterly Earnings on Tuesday
Supernus Pharmaceuticals (NASDAQ:SUPN) is projected to release its Q4 2025 earnings before the market opens on Tuesday, February 24, 2026, with analysts anticipating earnings of $0.41 per share. Insider selling activity was noted in late 2025, and institutional investors have adjusted their positions. Analyst ratings are mixed, with a consensus "Hold" rating and an average target price of $61.60.
Is Supernus Pharmaceuticals (SUPN) Still Attractive After A 30% One Year Share Price Gain
Supernus Pharmaceuticals (SUPN) has seen a 30% return over the last year, prompting a reevaluation of its current valuation. According to a Discounted Cash Flow (DCF) analysis, the stock appears significantly undervalued by 74.6% with an intrinsic value of $199.97 per share compared to its current price around $50.84. Additionally, its Price/Sales (P/S) ratio of 4.28x is close to the industry average and below Simply Wall St's Fair Ratio of 6.79x, further suggesting it may be undervalued.
Assessing Supernus Pharmaceuticals (SUPN) Valuation After Recent Share Price Momentum And Undervalued Narrative
Supernus Pharmaceuticals (SUPN) has experienced recent share price momentum, with gains over the past three months and year, and analysts suggesting it is undervalued by approximately 19%. While the company shows solid revenue growth and a fair value estimate of $61.33 against a current close of $51.34, concerns exist regarding rising SG&A and R&D costs, and reliance on key CNS products. Investors are encouraged to build their own narratives and consider underlying factors affecting the valuation.
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) will announce its fourth quarter and full year 2025 financial and business results after market close on Tuesday, February 24, 2026. Following this, Jack Khattar (President and CEO) and Tim Dec (Senior VP and CFO) will host a conference call at 4:30 p.m. ET to discuss these results and answer questions. A live webcast and replay will be available on the company's Investor Relations website.
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
Supernus Pharmaceuticals, Inc. will report its fourth quarter and full year 2025 financial and business results after market close on Tuesday, February 24, 2026. The company will host a conference call on the same day at 4:30 p.m. ET, led by President and CEO Jack Khattar and CFO Timothy Dec, to discuss the results and answer questions. A live webcast and replay will be available on the Company’s Investor Relations website.
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
Supernus Pharmaceuticals, Inc. announced it will release its fourth quarter and full year 2025 financial and business results after market close on Tuesday, February 24, 2026. President and CEO Jack Khattar and CFO Tim Dec will host a conference call on the same day at 4:30 p.m. ET to discuss the results and answer questions. A live webcast and replay will be available on the company's Investor Relations website.
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) announced it will report its fourth-quarter and full-year 2025 financial results on February 24, 2026, after market close. The company will host a conference call at 4:30 p.m. ET on the same day with CEO Jack Khattar and CFO Tim Dec to discuss the results and take questions. A live webcast and replay will be available on the company's investor relations website.
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
Supernus Pharmaceuticals, Inc. will report its fourth quarter and full year 2025 financial and business results after the market closes on Tuesday, February 24, 2026. Following the announcement, President and CEO Jack Khattar and SVP and CFO Tim Dec will host a conference call at 4:30 p.m. ET to discuss the results and answer questions. A live webcast and replay will be available on the company's Investor Relations website.
Supernus Pharmaceuticals to Report Q4 and Full Year 2025 Results
Supernus Pharmaceuticals (SUPN) is slated to release its fourth-quarter and full-year 2025 financial results after market close on February 24, 2026. Following the report, CEO Jack Khattar and CFO Tim Dec will host a conference call at 4:30 p.m. ET to discuss the results and address investor inquiries, with a live webcast available on the company's Investor Relations website. The company continues to focus on developing treatments for CNS diseases and expanding its product portfolio, with current analyst ratings projecting a potential rise in SUPN stock price.
Is Supernus Pharmaceuticals (SUPN) Offering Value After Strong Multi Year Share Price Gains
Supernus Pharmaceuticals (SUPN) is currently priced at US$49.37, showing significant long-term growth but a slight decline year-to-date. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 75.3%, with an estimated intrinsic value of $199.97 per share. Additionally, its Price/Sales ratio of 4.15x is below the industry average and Simply Wall St's proprietary "Fair Ratio" of 6.74x, further indicating potential undervaluation.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives Consensus Rating of "Hold" from Analysts
Analysts have issued a consensus "Hold" rating for Supernus Pharmaceuticals (NASDAQ:SUPN), with an average 12-month price target of $61.60. The company recently missed earnings and revenue expectations,
(SUPN) Volatility Zones as Tactical Triggers
This article provides an analysis of Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) highlighting divergent sentiment across different time horizons. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The report also includes multi-timeframe signal analysis indicating support and resistance levels for near, mid, and long-term periods.
A Look At Supernus Pharmaceuticals (SUPN) Valuation After Recent Steady Share Price Performance
Supernus Pharmaceuticals (SUPN) is attracting attention due to its recent steady share performance, with its stock closing at US$49.08 and showing a 24.32% one-year total shareholder return. Analysts have set a price target of US$61.33, implying it's undervalued. The optimistic narrative for SUPN's valuation is driven by expectations of an expanding CNS patient pool, innovative product launches, and pipeline advancements, along with a strong balance sheet.
Great Lakes Advisors LLC Has $3.40 Million Holdings in Supernus Pharmaceuticals, Inc. $SUPN
Great Lakes Advisors LLC decreased its holdings in Supernus Pharmaceuticals (NASDAQ:SUPN) by 49.9%, selling 70,950 shares and retaining 71,231 shares worth approximately $3.40 million. This move comes as other institutional investors adjusted their stakes, with some increasing and others decreasing their positions in the specialty pharmaceutical company. Supernus Pharmaceuticals recently missed Q3 earnings and revenue expectations, displaying a negative net margin despite an increase in year-over-year revenue.
Ruffer LLP Makes New $2.65 Million Investment in Supernus Pharmaceuticals, Inc. $SUPN
Ruffer LLP has invested $2.65 million in Supernus Pharmaceuticals (NASDAQ: SUPN), acquiring 55,385 shares, representing approximately 0.10% ownership. This new institutional investment comes amidst insider selling by Supernus executives and a mixed outlook from Wall Street analysts, who currently rate the stock as a "Hold" with an average price target of $61.60. The company recently missed its quarterly EPS and revenue estimates.
1 Healthcare Stock to Consider Right Now and 2 We Brush Off
This article evaluates three healthcare stocks, recommending Vertex Pharmaceuticals (VRTX) due to its strong revenue growth, high free cash flow, and stellar returns on capital. Conversely, it advises against Omnicell (OMCL) and Supernus Pharmaceuticals (SUPN) citing concerns about stagnating sales, decreasing efficiency, and subscale operations, respectively. The author emphasizes the importance of carefully selecting healthcare stocks given the sector's regulatory nature.
Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis: Exploring a 24.76% Potential Upside
Supernus Pharmaceuticals, Inc. (SUPN) is attracting investor interest due to its strong market position in CNS disease treatments and significant growth potential, evidenced by its diverse product portfolio and active pipeline. Despite current negative net income, the company boasts over $120 million in free cash flow and a positive analyst outlook with an average target price suggesting a 24.76% upside. Strategic developments like recent FDA approvals and ongoing clinical trials further solidify Supernus's promising future in the biopharmaceutical sector.
Supernus Pharmaceuticals, Inc. $SUPN Shares Bought by Universal Beteiligungs und Servicegesellschaft mbH
Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in Supernus Pharmaceuticals (NASDAQ: SUPN) by 28.4% in the third quarter, increasing its holdings to 109,836 shares valued at approximately $5.25 million. This comes amidst mixed analyst ratings, with some upgrades to "buy" or "overweight" while the consensus remains "Hold" with an average price target of $61.60. The company's fundamentals show a recent earnings miss, with EPS of $0.46 against an $0.82 estimate and revenue of $170 million versus the $175.8 million consensus, alongside insider stock sales.
Price-Driven Insight from (SUPN) for Rule-Based Strategy
This article provides a price-driven analysis for Supernus Pharmaceuticals Inc. (NASDAQ: SUPN), highlighting weak near-term sentiment but potential long-term strength. It outlines various AI-generated trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis to guide investors.
Recent 3.5% pullback isn't enough to hurt long-term Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders, they're still up 64% over 5 years
Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have seen a 64% increase in share price over the last five years, outperforming the market average, and a 25% increase in the past year despite a recent 3.5% pullback. While the company's earnings per share have declined, revenue growth has been positive at a compound rate of 4.6% over the same five-year period. This suggests that investors may be prioritizing revenue growth over EPS.
Recent 3.5% pullback isn't enough to hurt long-term Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders, they're still up 64% over 5 years
Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have seen their investment grow by 64% over the past five years, outperforming the market average, despite a recent 3.5% pullback. While the company's earnings per share (EPS) declined over this period, revenue has grown at a compound rate of 4.6%. The article suggests that current positive sentiment and business momentum could make it an interesting time to examine the company further.
Recent 3.5% pullback isn't enough to hurt long-term Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders, they're still up 64% over 5 years
Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have seen a 64% gain over the last five years, despite a recent 3.5% pullback. While the company's earnings per share have decreased by 32% annually during this period, revenue has grown at a compound rate of 4.6% over the same five years. The article suggests that investors may be focusing on revenue growth rather than EPS.
Supernus Pharmaceuticals (SUPN) Stock Analysis: Exploring A 22.67% Potential Upside
Supernus Pharmaceuticals (SUPN) is a healthcare company specializing in CNS treatments, with a current market cap of $2.87 billion. Analysts project a potential upside of 22.67% from its current price of $50, with an average target price of $61.33. While the company demonstrates revenue growth and substantial free cash flow, it currently shows negative EPS and does not offer dividends, characteristic of a growth-oriented firm reinvesting in its diverse product portfolio and pipeline.
(SUPN) Price Dynamics and Execution-Aware Positioning
This article analyzes Supernus Pharmaceuticals Inc. (NASDAQ: SUPN), highlighting a strong near-term sentiment towards a long-term positive bias, with support being tested. It identifies an exceptional 47.9:1 risk-reward setup targeting a 13.5% gain versus 0.3% risk. The analysis provides three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for various holding periods.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Rating of "Hold" by Analysts
Supernus Pharmaceuticals (NASDAQ:SUPN) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $61.60. Recent insider transactions show executives selling shares, and institutional investors have adjusted their stakes. The company's last reported quarterly earnings missed analyst estimates for both EPS and revenue, though revenue saw a year-over-year increase.
Cantor Fitzgerald reiterates Overweight rating on Supernus Pharmaceuticals stock
Cantor Fitzgerald has reiterated its Overweight rating and $63.00 price target for Supernus Pharmaceuticals (NASDAQ:SUPN) following updated models that include changes to operating expense estimates and revenue projections. Despite a recent earnings miss in Q3 2025, where EPS was -$0.80 against a forecasted $0.14, the firm's price target remains unchanged, suggesting the stock is undervalued according to InvestingPro's Fair Value assessment. Stifel also raised its price target for Supernus due to the company successfully navigating a patent cliff and building a strong portfolio for future growth.
Supernus Pharmaceuticals, Inc. (SUPN) Hit a 52 Week High, Can the Run Continue?
This article from MSN discusses Supernus Pharmaceuticals, Inc. (SUPN) hitting a new 52-week high. It poses the question of whether the stock's upward trend can be sustained.
Cantor Fitzgerald reiterates Overweight rating on Supernus Pharmaceuticals stock By Investing.com
Cantor Fitzgerald has reiterated its Overweight rating and $63.00 price target for Supernus Pharmaceuticals (NASDAQ:SUPN). This affirmation comes after an updated financial model that incorporated new operating expense estimates and revenue projections for the company. Despite a recent Q3 2025 earnings miss, Supernus Pharmaceuticals exceeded revenue estimates, demonstrating strong financial performance and successful navigation of a patent cliff, according to analysts.
How Supernus Pharmaceuticals Inc. (SUPN) Affects Rotational Strategy Timing
This article analyzes Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) for rotational strategy timing, highlighting a strong sentiment across all horizons with an overweight bias. It presents institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. Key findings include an exceptional risk-reward short setup and AI-generated signals for support and resistance levels.
Supernus Pharmaceuticals Insider Sold Shares Worth $1,008,150, According to a Recent SEC Filing
An insider at Supernus Pharmaceuticals sold shares totaling $1,008,150, as reported in a recent SEC filing. This transaction, published on December 22, 2025, highlights ongoing insider activity within the company. Supernus Pharmaceuticals focuses on developing and commercializing treatments for central nervous system diseases.
Supernus Pharmaceuticals (SUPN) Is Up 6.0% After FDA Approval Of ONAPGO Parkinson’s Drug - Has The Bull Case Changed?
Supernus Pharmaceuticals recently received FDA approval for ONAPGO, a Parkinson's drug, which has contributed to a 6.0% increase in its stock. This approval strengthens its central nervous system portfolio alongside existing and late-stage candidates, despite projections of increasing SG&A and R&D costs leading to an operating loss this year. The company's investment narrative now focuses on converting its pipeline into long-term commercial franchises and achieving projected revenues of $837.3 million by 2028.
Strong Results Lifted Supernus Pharmaceuticals (SUPN) in Q3
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) saw strong results in Q3 2025, exceeding analyst expectations and leading to a raised fiscal year forecast. The company, a biopharmaceutical firm specializing in central nervous system diseases, was highlighted by Aristotle Small Cap Equity Fund for its growth potential, profitability, and free cash flow generation. The stock's one-month return was 8.74%, and it gained 39.09% over the last 52 weeks, with total revenue reaching $192.1 million in Q3 2025.
Strong Results Lifted Supernus Pharmaceuticals (SUPN) in Q3
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) saw strong Q3 results, beating analyst expectations and raising its fiscal year 2025 forecasts. The company's stock gained 39.09% over the last 52 weeks and Aristotle Capital Boston, LLC maintains its position, citing the company's differentiated product pipeline and existing neurology products as strong growth drivers. Supernus Pharmaceuticals was held by 29 hedge fund portfolios at the end of Q3 2025.
Supernus Pharmaceuticals (SUPN): Assessing Valuation After Recent CNS Portfolio Progress and ONAPGO Approval
Supernus Pharmaceuticals (SUPN) has seen its stock price increase by approximately 30% this year, outpacing many biotech peers, largely due to progress in its central nervous system portfolio and the FDA approval of ONAPGO. Despite this growth, the stock is currently trading at a discount to analyst targets, with a narrative fair value of $60.50 against its closing price of $47.28, suggesting it may still be undervalued given its pipeline progress and potential future earnings growth. However, persistent pricing pressure on core drugs or clinical setbacks for its late-stage candidates could impact this optimistic outlook.
(SUPN) and the Role of Price-Sensitive Allocations
This article provides an in-depth analysis of Supernus Pharmaceuticals Inc. (NASDAQ: SUPN), highlighting strong near-term sentiment and a long-term positive bias. It presents three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, emphasizing a robust risk-reward setup. Thomas H. Kee Jr. delivers key findings and actionable insights for potential investors.
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
Supernus Pharmaceuticals, Inc. announced that its President and CEO, Jack A. Khattar, will present at the Bank of America Securities 2025 CNS Therapeutics Virtual Conference on December 8, 2025, at 3:20 p.m. ET. A live audio webcast will be available on the company's website, with an archived replay accessible for 60 days. The company focuses on developing and commercializing treatments for central nervous system diseases.
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
Supernus Pharmaceuticals announced that its President and CEO, Jack A. Khattar, will present at the Bank of America Securities 2025 CNS Therapeutics Virtual Conference on December 8, 2025, at 3:20 p.m. ET. A live audio webcast of the presentation will be available on the company's website. The company specializes in developing and commercializing products for central nervous system (CNS) diseases.
Supernus Pharmaceuticals (SUPN) Is Down 17.4% After Raising 2025 Guidance Amid Margin and Supply Pressures – Has the Bull Case Changed?
Supernus Pharmaceuticals reported strong Q3 results, exceeding revenue and earnings expectations, primarily due to its neurology products and a raised 2025 revenue guidance. Despite this, the company faces challenges from higher acquisition-related expenses, operating margin pressures, and temporary supply constraints for ONAPGO. These issues have led to a 17.4% drop in stock value, with the investment narrative now focusing on overcoming these cost and supply hurdles for sustained growth.
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
Supernus Pharmaceuticals announced that President and CEO Jack A. Khattar will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025. Investors can arrange meetings with management and access a live audio webcast of the presentation. Supernus Pharmaceuticals is a biopharmaceutical company focused on CNS diseases.
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
Supernus Pharmaceuticals, Inc. announced that its President and CEO, Jack A. Khattar, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025. The company specializes in developing and commercializing treatments for central nervous system (CNS) diseases. A live audio webcast of the presentation will be available, with an archived replay accessible for 60 days on their website.
Supernus Pharmaceuticals Inc expected to post earnings of 28 cents a share - Earnings Preview
Supernus Pharmaceuticals Inc (SUPN) is projected to report a 2.8% increase in quarterly revenue to $180.523 million for the period ending September 30, 2025, with an expected earnings per share of 28 cents. Analysts currently rate the shares as "buy," with a median 12-month price target of $60.00. The company has a history of beating earnings estimates in recent quarters, suggesting a positive trend.
Supernus Announces Third Quarter 2025 Financial Results
Supernus Pharmaceuticals announced strong financial results for the third quarter of 2025, with total revenues increasing by 9% year-over-year to $192.1 million, driven by significant growth in its four key products: Qelbree, GOCOVRI, ZURZUVAE, and the newly launched ONAPGO. The company completed the acquisition of Sage Therapeutics and is updating its full-year 2025 revenue guidance upwards, while also addressing supply constraints for ONAPGO due to higher-than-expected demand.
Supernus Pharmaceuticals, Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025
Supernus Pharmaceuticals, Inc. announced its plan to release third-quarter 2025 financial and business results on November 4, 2025, after market close. President and CEO Jack Khattar and Senior Vice President and CFO Tim Dec will host a conference call at 4:30 p.m. ET to discuss the results and answer questions. The company, which specializes in CNS disease treatments, will make a live webcast and replay of the call available on its Investor Relations website.
Supernus Pharmaceuticals to Announce Third Quarter 2025
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) announced it will report its third quarter 2025 financial results after market close on Tuesday, November 4, 2025. President and CEO Jack Khattar and Senior Vice President and CFO Tim Dec will host a conference call at 4:30 p.m. ET to discuss the results. A live webcast and replay will be available on the company's Investor Relations website.
Attention Deficit Hyperactivity Disorder Pipeline Drugs - openPR.com
This report from DelveInsight highlights the pipeline drugs for Attention Deficit Hyperactivity Disorder (ADHD), featuring over 20 active players and 22+ pipeline therapies. Key developments include a Supernus Pharmaceuticals Inc. study on SPN-812 for young children and details on therapies from Cingulate Therapeutics, Otsuka Pharmaceutical, and MindMed. The report provides insights into emerging drugs, clinical trial assessments, and the therapeutic landscape for ADHD.
SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) Presents a Compelling Mix of Growth and Technical Momentum
SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) is highlighted as an attractive investment due to its strong fundamental growth traits and positive technical patterns. The company exhibits rapid earnings and revenue growth, robust financial health with no debt, and a strong pipeline in central nervous system treatments. Technical analysis shows positive momentum and a breakout pattern, suggesting potential for continued upward movement, making it a compelling option for growth-focused investors.
Piper Sandler reiterates Overweight rating on Supernus stock at $65 - Investing.com
This article from Investing.com indicates that there was an application error preventing the display of content. It only shows general website elements, copyright information, and a privacy statement. No substantive news content regarding Piper Sandler's rating on Supernus stock is available.
What Supernus Pharmaceuticals (SUPN)'s Strong Qelbree and GOCOVRI Sales Surprise Means For Shareholders
Supernus Pharmaceuticals exceeded Q2 revenue expectations by 7.4% due to strong sales of Qelbree and GOCOVRI, highlighting these products' increasing role in the CNS treatment market. Despite this positive performance and raised full-year revenue guidance, investors face concerns regarding potential generic competition for Qelbree and the company's reliance on a limited product portfolio, which could impact its longer-term growth.
Zacks.com featured highlights include United Natural Foods, Teladoc Health, Supernus and BRP - Yahoo Finance
This article from Zacks.com highlights four stocks—United Natural Foods (UNFI), Teladoc Health (TDOC), Supernus Pharmaceuticals (SUPN), and BRP Inc. (DOOO)—that demonstrate relative price strength amidst market volatility driven by US-China trade tensions. The article suggests that these stocks, backed by solid fundamentals and positive analyst estimate revisions, are poised for continued outperformance.
